Regeneron’s antibody cocktail REGN-EB3 (Inmazeb) first FDA-approved treatment for Ebola (Zaire Ebolavirus)
On Oct. 14, 2020, Regeneron announced that the FDA had approved Inmazeb (atoltivimab, maftivimab and odesivimab-ebgn) for the…
Mosquitoes’ taste for blood traced to four types of neurons
On Oct. 13, 2020, Howard Hughes Medical Institute Investigator Leslie Vosshall’s team at The Rockefeller University and colleagues…
Biotechnology | COVID-19 | NIH | Therapeutics
NIH launched its ACTIV-5 ‘Big Effect Trial’ evaluating Humanigen’s Lenzilumabas potential COVID-19 therapy
On Oct. 13, 2020, Humanigen announced that the National Institute of Allergy and Infectious Diseases (NIAID), had launched…
RedHill Biopharma announced partnerships to expand manufacturing for COVID-19 therapeutic candidate opaganib
On Oct. 13, 2020, RedHill Biopharma announced collaborations with two specialist pharmaceutical manufacturers in Europe and Canada to…
Racial differences in Alzheimer’s research focus of $15 million grant
On Oct. 12, 2020, the Washington University School of Medicine in St. Louis announced a $14.6 million grant…
Biotechnology | COVID-19 | Disease | Therapeutics | Vaccine
Relation between COVID-19 and Guillain-Barre syndrome in adults: a systematic review published
On Oct. 8, 2020, the relation between COVID-19 and Guillain-Barre syndrome in adults: a systematic review was published…
Biotechnology | COVID-19 | Disease | Medicine | NIH | Therapeutics
La Jolla Institute for Immunology awarded $1.4 million to study COVID-19 in Latino Americans
On Oct. 8, 2020, the La Jolla Institute for Immunology (LJI) announced it had been granted $1.4 million…
Lilly announced supply of potential COVID-19 antibody therapy for low- and middle-income countries
On Oct. 8, 2020, Eli Lilly and the Bill & Melinda Gates Foundation, as part of the COVID-19…
SIGA announced Public Health Agency of Canada intent to purchase up to 33,300 courses of Oral TPOXX
On Oct. 8, 2020, SIGA Technologies announced that the Public Health Agency of Canada (PHAC) has issued an…
Biotechnology | Chemical | CRISPR | Genomics | Therapeutics
The Nobel Prize in Chemistry for 2020 was awarded to Emmanuelle Charpentier and Jennifer A Doudna
On Oct. 7, 2020, the Nobel Prize in Chemistry 2020 was awarded to Emmanuelle Charpentier and Jennifer Doudna…
RedHill Biopharma’s Opaganib COVID-19 study passed second independent committee review
On Oct. 7, 2020, RedHill Biopharma announced that the U.S. Phase 2 study with opaganib (Yeliva, ABC294640)1 in…
RedHill Biopharma opaganib COVID-19 study passed second independent committee review
On Oct. 7, 2020, RedHill Biopharma announced that the U.S. Phase 2 study with opaganib (Yeliva, ABC294640)1 in…
Sorrento announced discovery of salicyn-30 small molecule that strongly inhibits SARS-CoV-2 infection
On Oct. 7, 2020, Sorrento Therapeutics announced that it had discovered a small molecule termed Salicyn-30 that demonstrated…
Mateon announced first patient enrolled in ARTI-19 multicenter interventional study of Artshield against COVID-19
On Oct. 7, 2020, Mateon Therapeutics announced the first patient enrolled this week in its Phase IV study…
NIH RADx initiative advanced six new COVID-19 testing technologies
On Oct. 6, 2020, the National Institutes of Health (NIH), working in collaboration with the Biomedical Advanced Research…
Hologic Panther Platform and HIV-1 Quant assay used in ‘HIV Cure’ research
On Oct. 6, 2020, Hologic announced that two studies in the Journal of Clinical Microbiology demonstrated the utility…
Mateon initiated commercialization of Artshield
On Oct. 5, 2020, Mateon Therapeutics announced that ArtiShieldTM had been approved for manufacture and marketing by the…
Johnson & Johnson completed acquisition of Momenta Pharmaceuticals for $65 billion
On Oct. 1, 2020, Johnson & Johnson announced it had successfully completed its acquisition of Momenta Pharmaceuticals, a…
Sorrento Therapeutics and ViralClear entered agreement to explore combination antibody plus antiviral therapy against COVID-19
On Sept. 30, 2020, ViralClear Pharmaceuticals and Sorrento Therapeutics announced the companies were exploring the synergistic potential of…
Bio-Techne announced opening of GMP manufacturing facility in Twin Cities
On Sept. 30, 2020, Bio-Techne announced the opening of its approximately 61,000 square foot state-of-the-art GMP (Good Manufacturing…
AXIM Biotechnologies filed patent for world’s first face mask designed to capture SARS-CoV-2 COVID-19
On Sept. 29, 2020, AXIM Biotechnologies announced that it had filed a provisional patent for a first-in-class face…
Tonix Pharma completed the purchase of a facility to house advanced development center for vaccine programs
On Sept. 28, 2020, Tonix Pharmaceuticals announced that it had completed the purchase a 40,000 square foot facility…
Pascal Biosciences confirmed specific cannabinoids combat Coronavirus
On Sept. 23, 2020, Pascal Biosciences announced the Company had confirmed an earlier report that certain cannabinoids block…
Brazil approved RedHill Biopharma’s phase 2/3 COVID-19 study with opaganib
On Sept. 22, 2020, RedHill Biopharma announced approval from the Brazilian Health Regulatory Agency (ANVISA) for its ongoing…
XBiotech to develop human antibody combination as candidate treatment for influenza-COVID-19 co-infection
On Sept. 21, 2020, XBiotech announced it was developing a new breakthrough candidate therapy it calls FLUVID for…
Lilly and Amgen announced manufacturing collaboration for COVID-19 antibody therapies
On Sept. 17, 2020, Eli Lilly and Amgen announced a global antibody manufacturing collaboration to significantly increase the…
Atossa Therapeutics received second positive safety assessment in clinical study of AT-301 Coronavirus nasal spray
On Sept. 17, 2020, Atossa Therapeutics announced a positive interim safety assessment from the second cohort of healthy…
COVID-19 | FDA | Therapeutics
AXIM Biotechnologies filed Emergency Use Authorization with COVID-19 rapid diagnostic test for neutralizing antibodies
On Sept. 16, 2020, AXIM Biotechnologies announced that it had filed an Emergency Use Authorization (EUA) application with…
New anti-infective drugs had a 14% speed advantage vs other drugs from 2000-2019
On Sept. 15, 2020, the Tufts Center for the Study of Drug Development reported that new anti-infective drugs…
Soligenix announced publication demonstrating thermostabilization of filovirus vaccine antigens
On Sept. 15, 2020, Soligenix announced publication of nonclinical results characterizing filovirus protein antigens (including for Ebola and…